The antisense AGT inhibitor IONIS-AGT-LRX significantly reduces plasma AGT levels and is well-tolerated in phase II trials as a monotherapy and as an add on to existing hypertension drugs [65]. The gene discussed is AGT; the disease is Hypertension.